See more : Goldlok Holdings(Guangdong) Co.,Ltd. (002348.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Arno Therapeutics, Inc. (ARNI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arno Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hycroft Mining Holding Corporation (HYMCW) Income Statement Analysis – Financial Results
- American Silver Mining Co. (ASLM) Income Statement Analysis – Financial Results
- Relia, Inc. (4708.T) Income Statement Analysis – Financial Results
- Placoplatre SA (MLPLC.PA) Income Statement Analysis – Financial Results
- American Environmental Energy, Inc. (AEEI) Income Statement Analysis – Financial Results
Arno Therapeutics, Inc. (ARNI)
About Arno Therapeutics, Inc.
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.89K | 485.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 7.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -7.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.89K | 485.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 8.65M | 14.84M | 13.48M | 8.54M | 5.69M | 4.14M | 5.44M | 9.77M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 4.76M | 6.65M | 3.46M | 2.30M | 0.00 | 886.59K | 1.52M | 2.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 4.76M | 6.65M | 3.46M | 2.30M | 1.96M | 886.59K | 1.52M | 2.32M | 18.36K | 15.27K | 17.73K | 11.78K | 35.57K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 13.41M | 21.49M | 16.94M | 10.84M | 7.65M | 5.03M | 6.96M | 12.08M | 18.36K | 15.27K | 17.73K | 11.78K | 35.57K |
| Cost & Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 13.41M | 21.49M | 16.94M | 10.84M | 7.65M | 5.03M | 6.96M | 12.08M | 18.36K | 15.27K | 17.73K | 11.78K | 35.57K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 7.66K | 41.95K | 17.74K | 7.85K | 28.77K | 19.34K | 28.15K | 206.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 28.40K | 143.00 | 18.57M | 6.36M | 0.00 | 0.00 | 0.00 | 1.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 228.49K | 236.56K | 206.30K | 171.86K | 15.29K | 54.54K | 30.85K | 21.69K | 302.61K | 11.55K | 19.34K | 45.47K | 369.00 | 713.00 | 707.00 | 707.00 | 708.00 |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -13.40M | -21.44M | -16.91M | -14.37M | -7.34M | -6.00M | -6.95M | -12.04M | -17.99K | -14.56K | -15.13K | -10.59K | -34.86K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -801.38% | -2,183.71% | 0.00% |
| Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | -13.41M | -21.49M | -16.94M | -10.84M | -7.65M | -5.03M | -6.96M | -12.08M | -18.36K | -15.27K | -15.84K | -11.30K | -35.57K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -838.82% | -2,329.48% | 0.00% |
| Total Other Income/Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 1.90M | 29.26M | -22.72M | -3.55M | -290.93K | 983.78K | 28.15K | -830.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 0.00 | 0.00 | 0.00 | 0.00 | -11.51M | 7.77M | -39.66M | -14.39M | -7.94M | -4.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 28.40K | 143.00 | 18.57M | 6.36M | 262.16K | -1.00M | -28.15K | 830.00K | -55.59K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 0.00 | 0.00 | 0.00 | 0.00 | -11.54M | 7.77M | -58.23M | -20.75M | -8.20M | -4.02M | -6.94M | -12.91M | 37.23K | -15.27K | -15.84K | -11.30K | -35.57K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -838.82% | -2,329.48% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.57 | 0.38 | -7.75 | -4.57 | -1.90 | -1.58 | -2.72 | -6.45 | 0.03 | -0.07 | -0.07 | -0.05 | -0.16 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.57 | 0.31 | -7.75 | -4.57 | -1.90 | -1.58 | -2.72 | -6.45 | 0.03 | -0.07 | -0.07 | -0.05 | -0.16 |
| Weighted Avg Shares Out | 0.00 | 0.00 | 0.00 | 0.00 | 20.41M | 20.38M | 7.52M | 4.54M | 4.31M | 2.55M | 2.55M | 2.00M | 1.25M | 229.21K | 229.21K | 229.21K | 229.21K |
| Weighted Avg Shares Out (Dil) | 0.00 | 0.00 | 0.00 | 0.00 | 20.41M | 24.81M | 7.52M | 4.54M | 4.31M | 2.55M | 2.55M | 2.00M | 1.25M | 229.21K | 229.21K | 229.21K | 229.21K |
Source: https://incomestatements.info
Category: Stock Reports